Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Malaria Falciparum Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

NCT06735209
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 1:55 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

NCT03278808
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Jul 23, 2026, 1:55 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States

NCT02153996
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 1:55 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Malaria CVD 36000; Gates INV090205

NCT07558122
View directory record Official record
Conditions
Malaria (Plasmodium Falciparum)
Interventions
PfSPZ Challenge (NF54), Wearable Biosensor Devices, Placebo
Biological · Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

NCT00312702
View directory record Official record
Conditions
Malaria, Plasmodium Falciparum Malaria
Interventions
Falciparum Malaria Protein 11 with AS02A adjuvant
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2018 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

NCT02174978
View directory record Official record
Conditions
Malaria
Interventions
FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI)
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

NCT00427167
View directory record Official record
Conditions
Malaria
Interventions
AMA1-C1/Alhydrogel + CPG 7909 (Saline), AMA1-C1/Alhydrogel + CPG 7909 (Phosphate), AMA1-C1/Alhydrogel + CPG 7909
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers

NCT03867331
View directory record Official record
Conditions
Malaria,Falciparum
Interventions
5 microgram VLPM01, 15 microgram VLPM01, 30 microgram VLPM01, Plasmodium falciparum challenge
Biological · Other
Lead sponsor
VLP Therapeutics
Industry
Eligibility
18 Years to 49 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

NCT00761020
View directory record Official record
Conditions
Malaria
Interventions
Mefloquine, Control
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

NCT03168854
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalation PfSPZ-CVac

NCT03083847
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Jul 23, 2026, 1:55 PM EDT
Completed No phase listed Observational

Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia

NCT03996967
View directory record Official record
Conditions
Pneumonia, Bacterial, Viral Infection, Clinical Pneumonia, Plasmodium Falciparum Malaria, Malaria, Infections, Respiratory
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
2 Months to 5 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites

NCT01994525
View directory record Official record
Conditions
Malaria
Interventions
PfRAS, Placebo, Challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Safety of Intravenous Artesunate

NCT00292942
View directory record Official record
Conditions
Malaria, Malaria, Cerebral
Interventions
Intravenous Artesunate, Placebo
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT05581641
View directory record Official record
Conditions
Malaria
Interventions
BNT165b1, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes

NCT02313376
View directory record Official record
Conditions
Malaria
Interventions
GAP3KO
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali

NCT02334462
View directory record Official record
Conditions
Malaria
Interventions
Pfs230D1M-EPA/Alhydrogel, Pfs25M-EPA/Alhydrogel, TWINRIX, Menactra
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Jul 23, 2026, 1:55 PM EDT
Recruiting Not applicable Interventional

Platelet-Directed Whole Blood Transfusion Strategy for Malaria

NCT05711485
View directory record Official record
Conditions
Severe Malaria, Thrombocytopenia
Interventions
Whole blood transfusion
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
6 Months to 59 Months
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jul 23, 2026, 1:55 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine

NCT01024686
View directory record Official record
Conditions
Malaria
Interventions
p52-/p36- GAP Vaccine
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Jul 23, 2026, 1:55 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults

NCT04268420
View directory record Official record
Conditions
Vaccine Reaction
Interventions
FMP013, ALFQ
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sanaria™ PfSPZ Challenge Vaccine

NCT01546389
View directory record Official record
Conditions
Malaria
Interventions
Sanaria™ PfSPZ Vaccine, Chloroquine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant

NCT00320658
View directory record Official record
Conditions
Malaria
Interventions
MSP1 42-C1/Alhydrogel, CPG 7909
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adaptive Interventions for Optimizing Malaria Control: a Cluster-Randomized SMART Trial

NCT04182126
View directory record Official record
Conditions
LLIN, PBO LLIN, IRS, Larviciding
Interventions
Regular long-lasting insecticidal nets, LLIN plus Piperonyl butoxide-treated LLIN, Long-lasting microbial larvicide, Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
6 Months and older
Enrollment
122,872 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 23, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

NCT00347555
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jul 23, 2026, 1:55 PM EDT